The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 788-794 , October 2008

A differential effect of 2 probiotics in the prevention of eczema and atopy: A double-blind, randomized, placebo-controlled trial

  • Kristin Wickens, PhD

      Affiliations

    • Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • Corresponding Author InformationReprint requests: Kristin Wickens, PhD, Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, P O Box 7343, Wellington South, Wellington, New Zealand.
    • ,
  • Peter N. Black, FRACP

      Affiliations

    • Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    • ,
  • Thorsten V. Stanley, FRCP

      Affiliations

    • Department of Paediatrics, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • ,
  • Edwin Mitchell, FRACP, DSc

      Affiliations

    • Department of Paediatrics, University of Auckland, Auckland, New Zealand
    • ,
  • Penny Fitzharris, FRACP

      Affiliations

    • Immunology Department, Auckland Hospital, Auckland, New Zealand
    • ,
  • Gerald W. Tannock, PhD

      Affiliations

    • Department of Microbiology and Immunology, University of Otago, Wellington, New Zealand
    • ,
  • Gordon Purdie, BSc

      Affiliations

    • Department of Public Health, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • ,
  • Julian Crane, FRACP

      Affiliations

    • Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • ,
  • Probiotic Study Group

Received 9 April 2008 ,Revised 3 July 2008 ,Accepted 14 July 2008.

  • Image Result

    Diagram showing the flow of participants in the placebo, L rhamnosus HN001, and B animalis subsp lactis HN019 groups.

    Diagram showing the flow of participants in the placebo, L rhamnosus HN001, and B animalis subsp lactis HN019 groups.

  • Image Result

    Kaplan-Meier plot showing the 2-year cumulative prevalence of eczema in infants taking placebo, L rhamnosus HN001, or B animalis subsp lactis HN019.

    Kaplan-Meier plot showing the 2-year cumulative prevalence of eczema in infants taking placebo, L rhamnosus HN001, or B animalis subsp lactis HN019.

  • Image Result

    Kaplan-Meier plot showing the 2-year cumulative prevalence of SCORAD ≥10 in infants taking placebo, L rhamnosus HN001, or B animalis subsp lactis HN019.

    Kaplan-Meier plot showing the 2-year cumulative prevalence of SCORAD ≥10 in infants taking placebo, L rhamnosus HN001, or B animalis subsp lactis HN019.

  • Image Result

    A, For each infant group (administered B animalis subsp lactis HN019, L rhamnosus HN001, or placebo), the percentage in which B animalis subsp lactis was detected at each time point (in months). B, Fo

    A, For each infant group (administered B animalis subsp lactis HN019, L rhamnosus HN001, or placebo), the percentage in which B animalis subsp lactis was detected at each time point (in months). B, For each infant group (administered B animalis subsp lactis HN019, L rhamnosus HN001, or placebo), the percentage in which L rhamnosus was detected at each time point (in months).

 Supported by the Health Research Council of New Zealand and Fonterra Co-operative Group (Auckland, New Zealand). Fonterra Co-operative Group provided the study capsules and maintained quality control of the products throughout the study. All other aspects of the study were conducted independently of Fonterra Co-operative Group.

 Disclosure of potential conflict of interest: K. Wickens has received research funding from the Health Research Council and Fonterra Co-operative Group. P. N. Black has received research funding from the Health Research Council of New Zealand, the Child Health Research Foundation, Fonterra Co-operative Group, and Boehringer-Ingelheim. T. V. Stanley has received research funding from the Health Research Council of New Zealand, Fonterra Co-operative Group, the Asthma and Respiratory Foundation of New Zealand, and the Wellington Medical Research Foundation. E. Mitchell has received research funding from the Child Health Research Foundation and the National Heart Foundation of New Zealand and has served as trustee in the past year for the Wilson & Sweet Trust and the Child Health Research Foundation. P. Fitzharris has received research funding from the Marsden Fund and the Foundation for Research, Science & Technology. G. W. Tannock has received research support from the Marsden Fund and the Foundation for Research, Science, and Technology. G. Purdie has received research funding from the Health Research Council of New Zealand, Fonterra Co-operative Group, and the Ministry of Health. J. Crane has received research funding from the Health Research Council of New Zealand, Fonterra Co-operative Group, Rex Medical, the Asthma and Respiratory Foundation of New Zealand, and the National Institute of Environmental Health Sciences.

PII: S0091-6749(08)01319-5

doi: 10.1016/j.jaci.2008.07.011

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 788-794 , October 2008

Article Tools

* Image Usage & Resolution